1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Challenges

6. Companion Diagnostics Market, by Technology
6.1. Introduction
6.2. Immunohistochemistry
6.3. In Situ Hybridization
6.4. Next-generation Sequencing
6.5. Polymerase Chain Reaction

7. Companion Diagnostics Market, by Indication
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Leukemia
7.5. Lung Cancer
7.6. Melanoma

8. Companion Diagnostics Market, by End User
8.1. Introduction
8.2. Biopharmaceutical Companies
8.3. Pharmaceutical
8.4. Reference Laboratories

9. California Companion Diagnostics Market

10. Florida Companion Diagnostics Market

11. Illinois Companion Diagnostics Market

12. New York Companion Diagnostics Market

13. Ohio Companion Diagnostics Market

14. Pennsylvania Companion Diagnostics Market

15. Texas Companion Diagnostics Market

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. Abbott Laboratories
17.2. Abnova Corporation
17.3. Agilent Technologies, Inc.
17.4. Almac Group
17.5. Amoy Diagnostics Co., Ltd.
17.6. Archerdx, Inc.
17.7. ARUP Laboratories
17.8. Biogenex Laboratories, Inc
17.9. bioMérieux SA
17.10. Danaher Corporation
17.11. Eli Lilly and Company
17.12. F. Hoffmann-La Roche AG
17.13. FOUNDATION MEDICINE, INC.
17.14. Guardant Health, Inc
17.15. Illumina, Inc.
17.16. Invivoscribe Technologies, Inc.
17.17. Myriad Genetics, Inc.
17.18. NG biotech
17.19. Q2 Solutions
17.20. R-Biopharm AG
17.21. Siemens Healthcare Private Limited
17.22. Sysmex Corporation
17.23. Thermo Fisher Scientific Inc.

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 3. UNITED STATES COMPANION DIAGNOSTICS MARKET: MARKET DYNAMICS
FIGURE 4. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (%)
FIGURE 5. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2026
FIGURE 7. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2026 (USD MILLION)
FIGURE 8. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 9. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2026 (USD MILLION)
FIGURE 10. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 11. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2026 (USD MILLION)
FIGURE 12. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 13. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2026 (USD MILLION)
FIGURE 14. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
FIGURE 16. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2026
FIGURE 18. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2026 (USD MILLION)
FIGURE 19. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 20. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2026 (USD MILLION)
FIGURE 21. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 22. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, 2018-2026 (USD MILLION)
FIGURE 23. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 24. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2026 (USD MILLION)
FIGURE 25. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 26. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY MELANOMA, 2018-2026 (USD MILLION)
FIGURE 27. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY MELANOMA, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 28. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 29. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2026
FIGURE 31. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2026 (USD MILLION)
FIGURE 32. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 33. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL, 2018-2026 (USD MILLION)
FIGURE 34. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 35. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, 2018-2026 (USD MILLION)
FIGURE 36. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 37. UNITED STATES COMPANION DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 38. UNITED STATES COMPANION DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 39. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES COMPANION DIAGNOSTICS MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES COMPANION DIAGNOSTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD MILLION)
TABLE 5. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY STATE, 2018-2026 (USD MILLION)
TABLE 6. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY STATE, 2018-2026 (USD MILLION)
TABLE 7. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY STATE, 2018-2026 (USD MILLION)
TABLE 8. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY STATE, 2018-2026 (USD MILLION)
TABLE 9. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2026 (USD MILLION)
TABLE 10. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY STATE, 2018-2026 (USD MILLION)
TABLE 11. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2018-2026 (USD MILLION)
TABLE 12. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY STATE, 2018-2026 (USD MILLION)
TABLE 13. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY STATE, 2018-2026 (USD MILLION)
TABLE 14. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY MELANOMA, BY STATE, 2018-2026 (USD MILLION)
TABLE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2026 (USD MILLION)
TABLE 16. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY STATE, 2018-2026 (USD MILLION)
TABLE 17. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL, BY STATE, 2018-2026 (USD MILLION)
TABLE 18. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY STATE, 2018-2026 (USD MILLION)
TABLE 19. UNITED STATES COMPANION DIAGNOSTICS MARKET: SCORES
TABLE 20. UNITED STATES COMPANION DIAGNOSTICS MARKET: BUSINESS STRATEGY
TABLE 21. UNITED STATES COMPANION DIAGNOSTICS MARKET: PRODUCT SATISFACTION
TABLE 22. UNITED STATES COMPANION DIAGNOSTICS MARKET: RANKING
TABLE 23. UNITED STATES COMPANION DIAGNOSTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 24. UNITED STATES COMPANION DIAGNOSTICS MARKET: MERGER & ACQUISITION
TABLE 25. UNITED STATES COMPANION DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 26. UNITED STATES COMPANION DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 27. UNITED STATES COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING
TABLE 28. UNITED STATES COMPANION DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 29. UNITED STATES COMPANION DIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Abnova Corporation
Agilent Technologies, Inc.
Almac Group
Amoy Diagnostics Co., Ltd.
Archerdx, Inc.
ARUP Laboratories
Biogenex Laboratories, Inc
bioMérieux SA
Danaher Corporation
Eli Lilly and Company
F. Hoffmann-La Roche AG
FOUNDATION MEDICINE, INC.
Guardant Health, Inc
Illumina, Inc.
Invivoscribe Technologies, Inc.
Myriad Genetics, Inc.
NG biotech
Q2 Solutions
R-Biopharm AG
Siemens Healthcare Private Limited
Sysmex Corporation
Thermo Fisher Scientific Inc.